Compare REVB & RAYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVB | RAYA |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.3M |
| IPO Year | N/A | 2022 |
| Metric | REVB | RAYA |
|---|---|---|
| Price | $1.15 | $4.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 107.2K | 30.1K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,101,325.00 |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.78 |
| 52 Week Low | $0.83 | $3.13 |
| 52 Week High | $60.48 | $736.99 |
| Indicator | REVB | RAYA |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 59.36 |
| Support Level | $1.03 | $3.70 |
| Resistance Level | $1.00 | $5.62 |
| Average True Range (ATR) | 0.08 | 0.46 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 93.03 | 72.33 |
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.